Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the ...

Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA ...

Furthermore, the study – led by investigators at Vanderbilt University Medical Center in collaboration with Alterity Therapeutics’ (ASX:ATH) – found QSM can distinguish MSA from Parkinson’s disease ...

Shares of Alterity Therapeutics (NASDAQ:ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 ...